HMGXB4

Across TCGA pan-cancer cohorts, HMGXB4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HMGXB4 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HMGXB4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated HMGXB4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where HMGXB4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.852	0.675	<.001	33	view →
HNSC	DFS	Median	III,IV	0.693	0.884	.016	16	view →
LSCC	OS	Median	III,IV	0.732	0.956	.012	10	view →
GBM	OS	Quartile	All	0.519	0.310	.012	4	view →
LUAD	OS	Median	All	0.995	0.896	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HMGXB4–PDAC (DFS)

Open the PDAC breakdown →